Evidence map›Paper›PMID 41047423›Full record

ArticlePituitary2025

USP8, USP48, BRAF and TP53 mutations in crooke cell adenoma.

Paulina Kober, Magdalena Szczepaniak, Monika Pękul, Natalia Rusetska, Beata J Mossakowska, Artur Kowalik, Maria Maksymowicz, Grzegorz Zieliński, Jacek Kunicki, Mateusz Bujko

Abstract read
In one paragraph

Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Paulina KoberDepartment of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Magdalena SzczepaniakDepartment of Molecular Diagnostics, Holy Cross Cancer Center, Kielce, Poland.
Monika PękulDepartment of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Natalia RusetskaDepartment of Experimental Immunotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Beata J MossakowskaDepartment of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Artur KowalikDepartment of Molecular Diagnostics, Holy Cross Cancer Center, Kielce, Poland.
Maria MaksymowiczDepartment of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Grzegorz ZielińskiDepartment of Neurosurgery, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Jacek KunickiDepartment of Neurosurgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Mateusz BujkoDepartment of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. mateusz.bujko@nio.gov.pl.

Funding

National Science Centre, Poland 2019/35/N/NZ5/03121
6 · The paper itself

Abstract

purposeCrooke cell adenomas (CCAs) are rare histological subtype of corticotroph pituitary adenomas (cPAs) commonly related to worse prognosis in patients. Notable progress in understanding of the molecular background of cPAs has been made recently but biology of CCAs remains poorly recognized. Results of our previous study suggested distinct frequency of the known recurrent mutations in CCAs than in sparsely and densely granulated cPAs. Thus, the aim was to determine the prevalence of USP8, USP48, BRAF and TP53 variants in a relatively large retrospective group of patients diagnosed with CCA.

methodsDNA was isolated from formalin-fixed and paraffin-embedded tissue of 29 CCAs (14 clinically functioning and 15 nonfunctioning). Sanger sequencing was used for the identification of USP8, USP48, BRAF hotspot variants, while semiconductor sequencing with Ion AmpliSeq TP53 Panel was used for analysis of TP53 sequence.

resultsUSP8 variants were found in 2 CCA patients with Cushing's disease (CD), whereas 3 TP53 variants were identified in 1 CCA patient with CD and 2 patients with clinically nonfunctioning CCAs. USP8 variants are less frequent in clinically functioning CCAs than functioning sparsely and densely granulated corticotroph tumors (p = 0.0271). TP53 variants are more common in CCAs as compared to other histological subtypes (p = 0.0164). One BRAF V600E variant and no USP48 variant were found.

conclusionCCAs have slightly distinct mutational profile then other histological subtypes of cPAs. Since clinical relevance of TP53 variants in corticotroph tumors was already documented, testing toward TP53 sequence changes in patients with CCAs should be considered.

Indexed as

AdenomaEndopeptidasesEndosomal Sorting Complexes Required for TransportPituitary NeoplasmsProto-Oncogene Proteins B-rafTumor Suppressor Protein p53Ubiquitin ThiolesteraseAdultAgedFemaleHumansMaleMiddle AgedMutationRetrospective StudiesBRAF protein, humanEndopeptidasesEndosomal Sorting Complexes Required for TransportProto-Oncogene Proteins B-rafTP53 protein, humanTumor Suppressor Protein p53Ubiquitin ThiolesteraseUSP8 protein, humanBRAFCorticotroph PitNETCrooke cell adenomaTP53USP48USP8

Identifiers

PMID41047423
PMCPMC12497664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.